SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-020817
Filing Date
2022-05-20
Accepted
2022-05-20 09:38:30
Documents
13
Period of Report
2022-05-19
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evok-8k_20220519.htm   iXBRL 8-K 46232
2 EX-3.1 evok-ex31_6.htm EX-3.1 13085
  Complete submission text file 0001564590-22-020817.txt   192156

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA evok-20220519.xsd EX-101.SCH 5601
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE evok-20220519_lab.xml EX-101.LAB 20074
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE evok-20220519_pre.xml EX-101.PRE 11943
7 EXTRACTED XBRL INSTANCE DOCUMENT evok-8k_20220519_htm.xml XML 3681
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

IRS No.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36075 | Film No.: 22945774
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences